

Recent Advances and Future Directions in Oncology: A Daylong Multitumor Educational Symposium in Partnership with the North Carolina Oncology Association and the South Carolina Oncology Society Joint Annual Conference

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following types of toxicity was commonly associated with capivasertib combined with fulvestrant, which demonstrated favorable activity in the Phase III CAPItello trial for patients with advanced HR-positive, HER2-low or HER2-negative breast cancer?
  - Hematologic
  - Neurologic
  - Gastrointestinal
  - Ocular
- In the DYNAMIC study, how did patients with Stage II colon cancer fare with circulating tumor DNA-guided management compared to standard management?
  - Recurrence-free survival (RFS) at 2 years was significantly better
  - RFS at 2 years was worse
  - RFS at 2 years was noninferior
  - More patients received adjuvant chemotherapy
- Which agent or regimen received FDA approval in 2023 for patients with HER2-positive, RAS wild-type metastatic colorectal cancer who experience disease progression after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy?
  - Pertuzumab/trastuzumab
  - T-DM1
  - Tucatinib/trastuzumab
  - None of the above
- Which of the following is the best description of TAR-200?
  - Radioactive implant
  - Wafer-based chemotherapy implant
  - Intravesical drug delivery system for gemcitabine
  - None of the above
- The Phase III VISION trial evaluating the addition of the radioligand  $^{177}\text{Lu}$ -PSMA-617 to standard therapy demonstrated which of the following outcomes among patients with previously treated PSMA-positive metastatic castration-resistant prostate cancer?
  - The addition of  $^{177}\text{Lu}$ -PSMA-617 led to improved PSA response rates and a statistically significant improvement in overall survival
  - The addition of  $^{177}\text{Lu}$ -PSMA-617 led to improved PSA response rates but not to a statistically significant improvement in overall survival
  - The addition of  $^{177}\text{Lu}$ -PSMA-617 did not improve PSA response rates or overall survival
  - None of the above
- Which of the following BTK inhibitors binds noncovalently/reversibly?
  - Acalabrutinib
  - Ibrutinib
  - Pirtobrutinib
  - Zanubrutinib
- What is the target of the antibody-drug conjugate upifitamab rilsodotin?
  - NaPi2B
  - WEE1 kinase
  - FR-alpha
  - Toll-like receptors
- Which of the following observations was reported in the Phase III SIENDO study evaluating maintenance selinexor versus placebo for patients responding to first-line platinum-based chemotherapy for advanced endometrial cancer?
  - Significant improvement in progression-free survival with selinexor
  - Differential efficacy with selinexor, based on p53 status
  - Frequent gastrointestinal toxicity with selinexor
  - All of the above

## POST-TEST

Recent Advances and Future Directions in Oncology: A Daylong Multitumor Educational Symposium in Partnership with the North Carolina Oncology Association and the South Carolina Oncology Society Joint Annual Conference

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Trastuzumab deruxtecan is approved for patients with which of the following subtypes of metastatic non-small cell lung cancer?
- a. HER2 amplified
  - b. HER2 overexpressing
  - c. HER2 mutant
10. What is the target of the antibody-drug conjugate datopotamab deruxtecan?
- a. cMET
  - b. HER2
  - c. TROP2
  - d. HER3
  - e. NRG1